Cognition Therapeutics
Clinical trials sponsored by Cognition Therapeutics, explained in plain language.
-
Could a new pill slow Alzheimer's? large trial underway
Disease control OngoingThis study tests an experimental drug called CT1812 in 540 people with early Alzheimer's. Participants receive either the drug or a placebo for 18 months to see if it slows down memory and thinking problems. The goal is to find a safe treatment that helps people maintain their da…
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated May 17, 2026 18:20 UTC
-
New drug access program offers hope for lewy body dementia patients
Disease control NO_LONGER_AVAILABLEThis program gives people with mild-to-moderate dementia with Lewy bodies access to an experimental drug called CT1812 (Zervimesine) for up to one year. It is designed for patients who either completed a related study or are referred by their doctor and meet specific health crite…
Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC